Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension-Reference-Cited by-同舟云学术

Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension

Published:2018-06-18 Issue: Volume: Page:
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Reinisch Walter¹,Gibson Peter R²,Sandborn William J³,Feagan Brian G⁴,Strauss Richard⁵,Johanns Jewel⁵,Padgett Lakshmi⁵,Adedokun Omoniyi J⁵,Colombel Jean-Frederic⁶,Collins Judith⁷,Rutgeerts Paul⁸,Tarabar Dino⁹,Marano Colleen⁵

Affiliation:

1. Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

2. Monash University and Alfred Hospital, Melbourne, VIC, Australia

3. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA

4. Robarts Research Institute, University of Western Ontario, London, ON, Canada

5. Immunology, Janssen Research & Development, LLC., Spring House, PA, USA

6. Icahn School of Medicine at Mount Sinai, New York, NY, USA

7. Oregon Health & Science University and Portland VA Medical Center, Portland, OR, USA

8. Division of Gastroenterology and Hepatology, University of Leuven, Gasthuisberg, Leuven, Belgium

9. Department of Gastroenterology, Military Medical Academy, Belgrade, Serbia

Funder

Janssen Research and Development

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/advance-article-pdf/doi/10.1093/ecco-jcc/jjy079/25171654/jjy079.pdf

Reference9 articles.

1. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis;Sandborn;Gastroenterology,2014

2. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis;Rutgeerts;Aliment Pharmacol Ther,2015

3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis;Sandborn;Gastroenterology,2014

4. Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 year;Gibson;Clin Transl Gastroenterol,2016

5. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study;Schroeder;N Engl J Med,1987

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study;Digestive and Liver Disease;2024-01

2. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension;Journal of Crohn's and Colitis;2023-08-31

3. Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon;Crohn's & Colitis 360;2023-07-01

4. Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies;Crohn's & Colitis 360;2023-07-01

5. The Efficacy of Currently Licensed Biologics for Treatment of Ulcerative Colitis: A Literature Review;Cureus;2023-04-15